Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Running, not enrolling · Phase 1

Conditions studied: Relapsed and Refractory Multiple Myeloma

In brief

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Key facts

Study ID

NCT04155749

Run by

Kite, A Gilead Company

People needed

40

Starts

2019-12-23

Expected to finish

2027-05-01

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
• Documented measurable disease
• Adequate organ function
• Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

You may not qualify if…

• Plasma Cell Leukemia or History of Plasma Cell Leukemia
• Patients with a history of severe hypersensitivity to DMSO should be excluded
• Contraindication to fludarabine or cyclophosphamide
• Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
• Active central nervous system disease involvement by malignancy or active CNS pathology

Where it is running

• Advanced Cellular Therapeutics Facility, DCAM 0800A — Chicago, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Froedtert Hospital/Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.